Fatigue is a key prognostic indicator for adverse outcomes in AML, ALL, and myelodysplastic syndromes. CAR T-cell therapy post-transplant shows a 48% complete remission rate in AML, though not ...
- Data collectively highlight revumenib's combination potential with current standard of care agents and support advancement into pivotal combination trials in the frontline setting - - 100% CRc ...
Panelists discuss how future AML treatment will likely involve sophisticated decisions about triplet combinations, optimal sequencing of targeted agents, and balancing efficacy with toxicity through ...
In the recent AUGMENT-101 trial, revumenib met the study goals of complete remission in patients with acute myeloid leukemia or acute lymphoid leukemia. The novel drug, revumenib, led to a 23% ...
Acute myeloid leukemia (AML) is one of the most challenging blood cancers. The disease moves quickly and needs aggressive treatment with chemotherapy, sometimes followed by a bone marrow transplant.
Acute myeloid leukemia (AML) is a type of blood and bone marrow cancer. AML can affect people of any age, but it is most common in adults. AML occurs when bone marrow produces abnormal blood cells, ...
Relapsed acute myeloid leukemia (AML) is when cancer returns after a period of remission. Refractory AML means cancer has not responded to multiple rounds of treatment. Both can affect your treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback